SOLEUS CAPITAL MANAGEMENT L P
Q4 2024 Form 13-F
GREENWICH, CONNECTICUT
CIK 0001802630
· CRD 294459
· SEC-registered investment adviser
$1.6B Reported Value Total
SOLEUS CAPITAL MANAGEMENT, L.P. reports 14 total accounts under management (AUM). There are 14 discretionary accounts valued at $2,335,377,666, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
14 funds
· $3.8B gross asset value
Hedge Fund: $3.0B · Private Equity Fund: $765.8M
Source: Form ADV filed 2026-04-27
Reported value
$1.6B
Quarter over quarter
-8.0%
Holdings
80
Top-10 concentration
49.8%
Key People
Form ADV owners & control persons
Guy Bezalel Levy
SOLE OWNER
Charles Arthur Davis
MEMBER
Stephen Nmn Friedman
MEMBER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2024 13F record
Q4 2024 13F filing summary
| Period of report | December 31, 2024 |
|---|---|
| Filed | February 14, 2025 |
| Form | 13F-HR |
| Reported value | $1.6B |
| Positions | 80 |
| Change in reported value | +23.2% |
| New positions | 24 |
| Exited positions | 30 |
| Position turnover | 49.1% |
| Top-10 concentration | 49.8% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 11, 2026
|
97 | $2.9B |
|
Q1 2026 13F
Filed May 14, 2026
|
93 | $2.5B |
|
Q4 2025 13F
Filed Feb 12, 2026
|
94 | $2.7B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
87 | $2.0B |
|
Q2 2025 13F
Filed Aug 15, 2025
|
94 | $1.5B |
|
Q1 2025 13F
Filed May 15, 2025
|
74 | $1.4B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
80 | $1.6B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
86 | $1.3B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
92 | $1.1B |
|
Q1 2024 13F
Filed May 15, 2024
|
90 | $1.3B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
73 | $901.2M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
90 | $1.1B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
101 | $899.5M |
|
Q1 2023 13F
Filed May 15, 2023
|
76 | $965.7M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
72 | $697.1M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
75 | $736.0M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
70 | $641.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
63 | $775.1M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
65 | $998.8M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
70 | $641.7M |
7 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | XBI C SPDR SER TR | $270.2M | 16.98% |
| 2 | NVCR NOVOCURE LTD | $81.6M | 5.13% |
| 3 | TGTX TG THERAPEUTICS INC | $80.7M | 5.07% |
| 4 | BMRN BIOMARIN PHARMACEUTICAL INC | $65.8M | 4.14% |
| 5 | KRYS KRYSTAL BIOTECH INC | $56.1M | 3.53% |
| 6 | GRFS GRIFOLS S A | $49.1M | 3.09% |
| 7 | AXGN AXOGEN INC | $48.7M | 3.06% |
| 8 | IOVA IOVANCE BIOTHERAPEUTICS INC | $48.5M | 3.05% |
| 9 | TEVA TEVA PHARMACEUTICAL INDS LTD | $46.1M | 2.9% |
| 10 | TERN TERNS PHARMACEUTICALS INC | $45.1M | 2.83% |
| 11 | ORGO ORGANOGENESIS HLDGS INC | $40.0M | 2.51% |
| 12 | NRIX NURIX THERAPEUTICS INC | $39.6M | 2.49% |
| 13 | UTHR UNITED THERAPEUTICS CORP DEL | $38.6M | 2.43% |
| 14 | CELC CELCUITY INC | $33.6M | 2.11% |
| 15 | SNDX SYNDAX PHARMACEUTICALS INC | $32.9M | 2.07% |
| 16 | JSPR JASPER THERAPEUTICS INC | $32.0M | 2.01% |
| 17 | IART INTEGRA LIFESCIENCES HLDGS C | $28.9M | 1.82% |
| 18 | NPCE NEUROPACE INC | $27.2M | 1.71% |
| 19 | AZN ASTRAZENECA PLC | $26.8M | 1.68% |
| 20 | CCCC C4 THERAPEUTICS INC | $25.1M | 1.58% |
Values as reported on the Q4 2024 Form 13F. Every position is in the holdings table below.